Skip to main content
logo
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.150
+0.040 (3.60%)
At close: Sep 5, 2025, 4:00 PM
1.160
+0.010 (0.87%)
After-hours: Sep 5, 2025, 7:37 PM EDT

Allogene Therapeutics Revenue

In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.

Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
229
Market Cap
255.16M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202422.00K-73.00K-76.84%
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 2020---
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson90.63B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company53.26B
Novo Nordisk49.11B
Revenue Rankings

ALLO News

More News